Healthrelated Quality of Life and Experiences of a Heart Rehabilitation Programme After Care for Infective Endocarditis.
Launched by REGION HALLAND · Nov 21, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether joining a heart rehabilitation program can help improve the health and quality of life for patients who have had infective endocarditis, a serious heart infection. The program involves participants doing physical exercises in a group setting, guided by a physiotherapist, twice a week for 12 weeks. Participants will also share their experiences and how they feel about their health through surveys and interviews at different points over the year.
To be eligible for this trial, participants must have been diagnosed with infective endocarditis and have completed their treatment. They should also be able to perform a specific exercise test. This study aims to understand not just the physical benefits of rehabilitation, but also how these patients feel about their recovery process, making it an important step in improving care for individuals with this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of infective endocarditis (IE) based on Dukes ISCVID criteria and discharged after treatment for IE from the Department of Infectious Diseases, Hospital of Halmstad, Region Halland, Sweden.
- Exclusion Criteria:
- • Not able to do a bicycle ergometer test or training.
About Region Halland
Region Halland is a leading healthcare authority in Sweden, dedicated to advancing medical research and improving patient care through innovative clinical trials. With a commitment to high ethical standards and rigorous scientific methodologies, Region Halland collaborates with researchers, healthcare professionals, and academic institutions to facilitate groundbreaking studies across various therapeutic areas. By prioritizing patient safety and engagement, Region Halland aims to contribute valuable insights to the medical community and enhance the quality of healthcare services within the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Halmstad, Halland, Sweden
Patients applied
Trial Officials
Ingrid Larsson, PhD,Prof
Study Director
Department of Health and Nursing, School of Health and Welfare, Halmstad, Sweden
Magnus Rasmussen, MD,PhD,Prof
Study Director
Department of Clinical Sciences Lund, Division of Infection Medicine, Lund University, Lund, Sweden
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported